Conroy, M. R.
O’Sullivan, H.
Collins, D. C.
Bambury, R. M.
Power, D.
Grossman, S.
O’Reilly, S.
Article History
Received: 4 September 2023
Revised: 5 March 2024
Accepted: 17 March 2024
First Online: 18 April 2024
Competing interests
: RB reports travel funding from Bayer, Janssen, Ipsen, BMS and Pfizer. HOS reports honoraria from Takeda and Amgen. SOR is Deputy Editor of this journal, and recused himself from all decisions about this paper. The other authors have no relevant financial or non-financial interests to disclose.
: Ethical approval to conduct this study was received from the Clinical Research Ethics Committee (CREC) of the Cork Teaching Hospitals, reference number ECM 4 (cc) 12/11/2019.